Cardiac Sarcoidosis

Journal of the American College of Cardiology

Volumn 68, Issue 4, 2016, Pages 411-421

  Birnie, David H ^a   Nery, Pablo B ^a   Ha, Andrew C ^b   Beanlands, Rob S B ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

atrioventricular block; clinically manifest; clinically silent; heart failure; sudden cardiac death; ventricular arrhythmias

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; NEOPTERIN; PREDNISONE; TROPONIN;

CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCARDIOGRAPHY; ENZYME BLOOD LEVEL; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART FASCICULAR BLOCK; HEART MUSCLE BIOPSY; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MASS SCREENING; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SUDDEN CARDIAC DEATH; THORAX RADIOGRAPHY; UVEITIS; CARDIOMYOPATHIES; CINE MAGNETIC RESONANCE IMAGING; DIAGNOSTIC IMAGING; PROCEDURES; PROGNOSIS;

CARDIOMYOPATHIES; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SARCOIDOSIS;

EID: 84990935154     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.03.605     Document Type: Review

References (74)

1. 1 McGrath, D.S., Goh, N., Foley, P.J., et al. Sarcoidosis: genes and microbes—soil or seed?. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001), 149–164.
2. 2 Morimoto, T., Azuma, A., Abe, S., et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 31 (2008), 372–379.
3. 3 Hillerdal, G., Nöu, E., Osterman, K., et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 130 (1984), 29–32.
4. 4 Valeyre, D., Prasse, A., Nunes, H., et al. Sarcoidosis. Lancet 383 (2014), 1155–1167.
5. 5 Rybicki, B.A., Iannuzzi, M.C., Frederick, M.M., et al., for the ACCESS Research Group. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 164 (2001), 2085–2091.
6. 6 Rybicki, B.A., Sinha, R., Iyengar, S., et al., for the SAGA Study Consortium. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study. Genes Immun 8 (2007), 379–386.
7. 7 Naruse, T.K., Matsuzawa, Y., Ota, M., et al. HLA-DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens 56 (2000), 52–57.
8. 8 Takashige, N., Naruse, T.K., Matsumori, A., et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 54 (1999), 191–193.
9. 9 Iwai, K., Tachibana, T., Takemura, T., et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 43 (1993), 372–376.
10. 10 Perry, A., Vuitch, F., Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 119 (1995), 167–172.
11. 11 Kandolin, R., Lehtonen, J., Airaksinen, J., et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131 (2015), 624–632.
12. 12 Al-Kindi, S.G., Oliveira, G.H., Letter by Al-Kindi and Oliveira regarding article “Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.”. Circulation, 132, 2015, e211.
13. 13 Kandolin, R., Lehtonen, J., Kupari, M., Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 4 (2011), 303–309.
14. 14 Nery, P.B., Beanlands, R.S., Nair, G.M., et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 25 (2014), 875–881.
15. 15 Nery, P.B., Mc Ardle, B.A., Redpath, C.J., et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 367 (2014), 364–374.
16. 16 Tung, R., Bauer, B., Schelbert, H., et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: the potential role of occult inflammation in arrhythmogenesis. Heart Rhythm 12 (2015), 2488–2498.
17. 17 Segura, A.M., Radovancevic, R., Demirozu, Z.T., et al. Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device. Cardiovasc Pathol 23 (2014), 17–20.
18. 18 Roberts, W.C., Chung, M.S., Ko, J.M., et al. Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation. Am J Cardiol 113 (2014), 706–712.
19. 19 Philips, B., Madhavan, S., James, C.A., et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol 7 (2014), 230–236.
20. 20 Kandolin, R., Lehtonen, J., Graner, M., et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 270 (2011), 461–468.
21. 21 Sharma, P.S., Lubahn, J.G., Donsky, A.S., et al. Diagnosing cardiac sarcoidosis clinically without tissue confirmation. Proc (Bayl Univ Med Cent) 22 (2009), 236–238.
22. 22 Keijsers, R.G., Veltkamp, M., Grutters, J.C., Chest imaging. Clin Chest Med 36 (2015), 603–619.
23. 23 Chung, Y.M., Lin, Y.C., Liu, Y.T., et al. Uveitis with biopsy-proven sarcoidosis in Chinese—a study of 60 patients in a uveitis clinic over a period of 20 years. J Chin Med Assoc 70 (2007), 492–496.
24. 24 Mehta, D., Lubitz, S.A., Frankel, Z., et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133 (2008), 1426–1435.
25. 25 Nagai, T., Kohsaka, S., Okuda, S., et al. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 146 (2014), 1064–1072.
26. 26 Nagao, S., Watanabe, H., Sobue, Y., et al. Electrocardiographic abnormalities and risk of developing cardiac events in extracardiac sarcoidosis. Int J Cardiol 189 (2015), 1–5.
27. 27 Patel, M.R., Cawley, P.J., Heitner, J.F., et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 120 (2009), 1969–1977.
28. 28 Pizarro, C., Goebel, A., Dabir, D., et al. Cardiovascular magnetic resonance-guided diagnosis of cardiac affection in a Caucasian sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 32 (2016), 325–335.
29. 29 Schuller, J.L., Olson, M.D., Zipse, M.M., et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol 22 (2011), 1243–1248.
30. 30 Nery, P.B., Keren, A., Healey, J., et al. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol 29 (2013), 1015.e1–1015.e3.
31. 31 Ayyala, U.S., Nair, A.P., Padilla, M.L., Cardiac sarcoidosis. Clin Chest Med 29 (2008), 493–508 ix.
32. 32 Agarwal, A., Sulemanjee, N.Z., Cheema, O., et al. Cardiac sarcoid: a chameleon masquerading as hypertrophic cardiomyopathy and dilated cardiomyopathy in the same patient. Echocardiography 31 (2014), E138–E141.
33. 33 Sköld, C.M., Larsen, F.F., Rasmussen, E., et al. Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med 252 (2002), 465–471.
34. 34 Burstow, D.J., Tajik, A.J., Bailey, K.R., et al. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 63 (1989), 478–482.
35. 35 Joyce, E., Ninaber, M.K., Katsanos, S., et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 17 (2015), 51–62.
36. 36 Iannuzzi, M.C., Rybicki, B.A., Teirstein, A.S., Sarcoidosis. N Engl J Med 357 (2007), 2153–2165.
37. 37 Vorselaars, A.D., van Moorsel, C.H., Zanen, P., et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med 109 (2015), 279–285.
38. 38 Kandolin, R., Lehtonen, J., Airaksinen, J., et al. Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis. Am J Cardiol 116 (2015), 960–964.
39. 39 Ichinose, A., Otani, H., Oikawa, M., et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol 191 (2008), 862–869.
40. 40 Cummings, K.W., Bhalla, S., Javidan-Nejad, C., et al. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics 29 (2009), 89–103.
41. 41 Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005), 1683–1690.
42. 42 Patel, A.R., Klein, M.R., Chandra, S., et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail 13 (2011), 1231–1237.
43. 43 Greulich, S., Deluigi, C.C., Gloekler, S., et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. J Am Coll Cardiol Img 6 (2013), 501–511.
44. 44 Murtagh, G., Laffin, L.J., Beshai, J.F., et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging, 9, 2016, e003738.
45. 45 Crouser, E.D., Ono, C., Tran, T., et al. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 189 (2014), 109–112.
46. 46 White, J.A., Rajchl, M., Butler, J., et al. Active cardiac sarcoidosis: first clinical experience of simultaneous positron emission tomography—magnetic resonance imaging for the diagnosis of cardiac disease. Circulation 127 (2013), e639–e641.
47. 18F-FDG. J Nucl Med 46 (2005), 1522–1530.
48. 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26 (2005), 1538–1543.
49. 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53 (2012), 241–248.
50. 50 Birnie, D.H., Sauer, W.H., Bogun, F., et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11 (2014), 1305–1323.
51. 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 28 (2014), 393–403.
52. 52 Bennett, M.K., Gilotra, N.A., Harrington, C., et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009. Circ Heart Fail 6 (2013), 676–684.
53. 53 Liang, J.J., Hebl, V.B., DeSimone, C.V., et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. J Am Coll Cardiol HF 2 (2014), 466–473.
54. 54 Leone, O., Veinot, J.P., Angelini, A., et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 21 (2012), 245–274.
55. 55 Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 27 (2007), 89–102.
56. 56 Judson, M.A., Baughman, R.P., Teirstein, A.S., Terrin, M.L., Yeager, H. Jr., for the ACCESS Research Group. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999), 75–86.
57. 57 Grutters, J.C., van den Bosch, J.M., Corticosteroid treatment in sarcoidosis. Eur Respir J 28 (2006), 627–636.
58. 58 Sadek, M.M., Yung, D., Birnie, D.H., et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 29 (2013), 1034–1041.
59. 59 Yazaki, Y., Isobe, M., Hiroe, M., et al., for the Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88 (2001), 1006–1010.
60. 60 Nagai, S., Yokomatsu, T., Tanizawa, K., et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med, 53, 2014, 2761.
61. 61 Müller-Quernheim, J., Kienast, K., Held, M., et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 14 (1999), 1117–1122.
62. 62 Demeter, S.L., Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 94 (1988), 202–203.
63. 63 Judson, M.A., Baughman, R.P., Costabel, U., et al., for the Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 31 (2008), 1189–1196.
64. 64 Donsky, A.S., Escobar, J., Capehart, J., et al. Heart transplantation for undiagnosed cardiac sarcoidosis. Am J Cardiol 89 (2002), 1447–1450.
65. 65 Kumar, S., Barbhaiya, C., Nagashima, K., et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 8 (2015), 87–93.
66. 66 Jefic, D., Joel, B., Good, E., et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 6 (2009), 189–195.
67. 67 Koplan, B.A., Soejima, K., Baughman, K., et al. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 3 (2006), 924–929.
68. 68 Betensky, B.P., Tschabrunn, C.M., Zado, E.S., et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 9 (2012), 884–891.
69. 69 Schuller, J.L., Zipse, M., Crawford, T., et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 23 (2012), 925–929.
70. 70 Kron, J., Sauer, W., Schuller, J., et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 15 (2013), 347–354.
71. 71 Chiu, C.Z., Nakatani, S., Zhang, G., et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 95 (2005), 143–146.
72. 72 Dhôte, R., Vignaux, O., Blanche, P., et al. [Value of MRI for the diagnosis of cardiac involvement in sarcoidosis]. Rev Med Interne 24 (2003), 151–157.
73. 73 Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128 (2005), 30–35.
74. 74 Vignaux, O., Dhote, R., Duboc, D., et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 26 (2002), 762–767.